Cargando…
Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severe aplastic anemia (SAA). A total of 5 consecutive adults were enrolled. The patients received ATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks. If necessary, a second course was p...
Autores principales: | Li, Ning, Song, Yongping, Zhou, Jian, Fang, Baijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475035/ https://www.ncbi.nlm.nih.gov/pubmed/23044093 http://dx.doi.org/10.1186/1756-8722-5-61 |
Ejemplares similares
-
Effect of arsenic trioxide on the Tregs ratio and the levels of IFN-γ, IL-4, IL-17 and TGF-β1 in the peripheral blood of severe aplastic anemia patients
por: Zhao, Juanjuan, et al.
Publicado: (2020) -
The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
por: Işık, Ayşe, et al.
Publicado: (2013) -
Acquired aplastic anemia: Is bystander insult to autologous hematopoiesis driven by immune surveillance against malignant cells?
por: Zhao, Xi-Chen, et al.
Publicado: (2020) -
Human leukocyte antigen-DRB1 gene polymorphism and aplastic anemia: A meta-analysis
por: Liang, Lijie, et al.
Publicado: (2023) -
APC/C is essential for hematopoiesis and impaired in aplastic anemia
por: Wang, Jia, et al.
Publicado: (2017)